Roger J M Bruggemann
Overview
Explore the profile of Roger J M Bruggemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
2155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burger D, Nijboer L, Ghobreyal M, Maertens J, Blijlevens N, Hilbrands L, et al.
Clin Pharmacokinet
. 2024 Nov;
63(11):1529-1546.
PMID: 39509076
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often have polypharmacy making them at risk...
2.
Bernts L, Bruggemann R, Jansen A, Jager N, Wertheim H, Drenth J, et al.
J Antimicrob Chemother
. 2024 Nov;
80(1):182-191.
PMID: 39508371
Background: The EASL cystic liver disease guideline states that drug penetration at the site of infection (liver cyst) is essential for successful treatment, but pharmacokinetic (PK) data on cyst penetration...
3.
Korzilius J, Gompelman M, Jager N, Rovers C, Bruggemann R, Wanten G
J Antimicrob Chemother
. 2024 Nov;
80(1):314.
PMID: 39499218
No abstract available.
4.
Ergun M, Jansen A, Hilbrands L, de Kort E, Kunst H, Reijers M, et al.
J Antimicrob Chemother
. 2024 Jun;
79(8):1801-1810.
PMID: 38935893
Background: Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. This...
5.
van Rhee K, Bruggemann R, Roberts J, Sjovall F, Van Hest R, Elbers P, et al.
J Clin Pharmacol
. 2024 May;
64(9):1165-1172.
PMID: 38736038
Recent studies have explored the influence of obesity and critical illness on ciprofloxacin pharmacokinetics. However, variation across the subpopulation of individuals with obesity admitted to the intensive care unit (ICU)...
6.
Jansen A, Snijdelaar K, Keizer R, Spriet I, Dreesen E, Bruggemann R, et al.
Clin Pharmacokinet
. 2024 Mar;
63(5):645-656.
PMID: 38532053
Background And Objective: Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is of utmost importance as achieving adequate antifungal exposure is associated with...
7.
Jansen A, Eggermont M, Wilms E, Aziz S, Reijers M, Roukema J, et al.
Med Mycol
. 2024 Mar;
62(3).
PMID: 38444173
Limited data on the clinical management of drug-drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations...
8.
Mekking X, Velthoven-Graafland K, Teulen M, Bruggemann R, Te Brake L, Jager N
J Antimicrob Chemother
. 2024 Feb;
79(4):883-890.
PMID: 38416407
Objective: To develop and validate an UPLC-MS/MS assay for simultaneous determination of the total concentration of ceftazidime, ciprofloxacin, flucloxacillin, piperacillin, tazobactam, sulfamethoxazole, N-acetyl sulfamethoxazole and trimethoprim, and the protein-unbound concentration...
9.
Zhang T, Krekels E, Smit C, van Dongen E, Bruggemann R, Knibbe C
Clin Pharmacokinet
. 2023 Nov;
63(1):79-91.
PMID: 37971650
Background And Objective: The latest vancomycin guideline recommends area under the curve (AUC)-targeted dosing and monitoring for efficacy and safety. However, guidelines for AUC-targeted starting dosing in patients with obesity...
10.
Bury D, Wolfs T, Ter Heine R, Muilwijk E, van der Elst K, Tissing W, et al.
J Antimicrob Chemother
. 2023 Oct;
78(12):2886-2889.
PMID: 37864491
Objectives: To study the isavuconazole pharmacokinetics in a real-life paediatric cohort and confirm whether the isavuconazole exposures are within the adult exposure range. Furthermore, we are the first to describe...